Acute leukemia of ambiguous lineage entities
| Acute leukemia of ambiguous lineage . |
|---|
| MPAL with defining genetic alterations |
| MPAL with BCR::ABL1 |
| MPAL with t(v;11q23.3); KMT2A rearranged |
| MPAL with ZNF384 rearrangement |
| MPAL with BCL11B activation |
| MPAL with defining immunophenotypic changes |
| B/myeloid MPAL |
| T/myeloid MPAL |
| B/T/myeloid MPAL |
| B/T MPAL |
| Acute undifferentiated leukemia (AUL)∗ |
| ALAL, NOS† |
| Acute leukemia of ambiguous lineage . |
|---|
| MPAL with defining genetic alterations |
| MPAL with BCR::ABL1 |
| MPAL with t(v;11q23.3); KMT2A rearranged |
| MPAL with ZNF384 rearrangement |
| MPAL with BCL11B activation |
| MPAL with defining immunophenotypic changes |
| B/myeloid MPAL |
| T/myeloid MPAL |
| B/T/myeloid MPAL |
| B/T MPAL |
| Acute undifferentiated leukemia (AUL)∗ |
| ALAL, NOS† |
NOS, not otherwise specified.
AUL is defined by a lack of lineage-specific markers (as outlined in Table 2). Based on a recent multiinstitutional study, cases with a partial or single full myeloid marker can be considered as AUL.11 Cases with immunophenotype of AUL but with cytogenetic abnormalities and molecular findings diagnostic of AML with myelodysplasia-related cytogenetic abnormalities or AML with myelodysplasia-related mutation should be diagnosed as AML.
Rare cases may fulfill neither the criteria for MPAL nor acute leukemia of a single lineage or may lack all the lineage-specific markers of Table 2. Such cases are best referred to as ALAL, NOS.